In CAD with GI bleeding, higher mortality with triple therapy

In CAD with GI bleeding, higher mortality with triple therapy

(HealthDay)—For patients with lower gastrointestinal bleeding (LGIB) and coronary artery disease (CAD), triple therapy is associated with increased risk of mortality at 90 days after adjustment for confounding variables, according to a study published online Nov. 20 in the Journal of Gastroenterology and Hepatology.

Parita Patel, M.D., from the University of Chicago Medical Center, and colleagues conducted a involving 716 patients hospitalized with LGIB and CAD while on aspirin. Patients were identified using a validated algorithm and were classified by use of aspirin monotherapy (65.9 percent of patients); aspirin and thienopyridine (dual antiplatelet therapy [DAPT]; 25 percent); or aspirin, thienopyridine, and systemic anticoagulant (; 9.1 percent).

The researchers found that triple therapy was correlated with increased risk of 90-day and six-month mortality on univariate analysis (hazard ratios, 3.12 and 2.46, respectively). Holding anticoagulation was correlated with increased mortality at 90 days (hazard ratio, 2.3). Triple therapy remained associated with higher 90-day mortality after adjustment for confounding variables (hazard ratio, 3.23).

"The results of this study demonstrate higher comorbidity-adjusted 90-day and six-month mortality for those on triple therapy compared to those on aspirin monotherapy or DAPT. Our data additionally suggests that mortality may be driven by discontinuation of anticoagulation on discharge in patients initially treated with triple ," the authors write.


Explore further

Risk up for triple Tx versus DAPT in DES implantation with A-fib

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2017 HealthDay. All rights reserved.

Citation: In CAD with GI bleeding, higher mortality with triple therapy (2017, December 6) retrieved 15 November 2019 from https://medicalxpress.com/news/2017-12-cad-gi-higher-mortality-triple.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments